CA
NZ
UK
AU
IND
US
…
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. It serves hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Nuo Therapeutics Inc is an OTCQB‑listed company operating in the therapeutic/biotech sector with limited publicly available information about its programs and operations. Its long‑term growth could be driven by successful clinical development, regulatory approvals, strategic partnerships and the ability to secure financing, which may benefit investors seeking exposure to early‑stage healthcare opportunities.
Key investment risks include early‑stage development uncertainty, a high likelihood of future capital raises and shareholder dilution, low trading liquidity on the OTC market and the potential for regulatory or clinical setbacks.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -2.51M | -2.32M | -3.17M | -3.17M | -0.09M |
| Net income | -2.51M | -2.32M | -3.17M | -3.17M | -0.09M |
| Selling general administrative | 4.73M | 3.52M | 3.65M | 3.41M | 0.09M |
| Gross profit | 2.22M | 1.06M | 0.48M | 0.09M | 0.00M |
| Reconciled depreciation | 0.16M | 0.10M | 0.11M | 0.07M | - |
| Ebit | - | - | - | -3.32M | -0.09M |
| Ebitda | - | - | - | -3.10M | -0.09M |
| Operating income | -2.52M | -2.46M | -3.17M | -3.32M | -0.09M |
| Interest expense | - | - | 0.00M | 0.00M | 0.00M |
| Tax provision | - | - | - | - | 0.00M |
| Net interest income | -0.00M | 0.00M | -0.00M | -0.00M | 0.00M |
| Total revenue | 3.31M | 1.37M | 0.61M | 0.11M | 0.00M |
| Total operating expenses | 5.83M | 3.82M | 3.78M | 3.43M | 0.09M |
| Cost of revenue | 1.10M | 0.30M | 0.13M | 0.02M | 0.00M |
| Total other income expense net | 0.01M | 0.13M | - | 0.15M | - |
| Net income from continuing ops | -2.51M | -2.32M | -3.17M | -3.17M | -0.09M |
| Net income applicable to common shares | - | - | - | -3.17M | -0.89M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1.85M | 1.19M | 1.88M | 3.05M | 0.15M |
| Other current assets | 0.06M | 0.16M | 0.17M | 0.06M | 0.00M |
| Total liab | 2.80M | 0.68M | 0.84M | 0.86M | 0.67M |
| Total stockholder equity | -0.96M | 0.51M | 1.04M | 2.19M | -0.52M |
| Common stock | - | - | - | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -34.77M | -32.26M | -29.94M | -26.76M | -23.59M |
| Other liab | - | - | - | -0.00M | - |
| Cash | 0.55M | 0.28M | 0.93M | 2.05M | 0.15M |
| Total current liabilities | 1.31M | 0.58M | 0.67M | 0.60M | 0.67M |
| Property plant equipment | - | - | - | 0.41M | - |
| Total current assets | 1.38M | 0.84M | 1.56M | 2.63M | 1.47M |
| Net tangible assets | - | - | - | 2.19M | 0.79M |
| Net receivables | 0.56M | 0.25M | 0.25M | 0.09M | - |
| Long term debt | 0.50M | - | - | - | - |
| Inventory | 0.21M | 0.15M | 0.21M | 0.24M | - |
| Accounts payable | 0.44M | 0.22M | 0.39M | 0.40M | 0.53M |
| Non current assets total | 0.47M | 0.35M | 0.31M | 0.41M | 0.00M |
| Capital lease obligations | 0.10M | 0.16M | 0.26M | 0.34M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.15M | -0.01M | -0.06M | 0.00M |
| Change to liabilities | - | - | - | 0.02M | 0.01M |
| Total cashflows from investing activities | - | - | - | -0.06M | -0.06M |
| Net borrowings | 0.50M | 0.00M | - | - | - |
| Total cash from financing activities | 1.40M | 1.74M | 2.00M | 4.46M | 1.37M |
| Change to operating activities | - | - | - | -0.16M | -0.05M |
| Net income | -2.51M | -2.32M | -3.17M | -3.17M | -0.09M |
| Change in cash | 0.27M | -0.64M | -1.18M | 0.69M | 1.25M |
| Begin period cash flow | 0.28M | 0.93M | 2.11M | 1.41M | 0.16M |
| End period cash flow | 0.55M | 0.28M | 0.93M | 2.11M | 0.15M |
| Total cash from operating activities | -0.86M | -2.23M | -3.17M | -3.71M | -0.12M |
| Issuance of capital stock | 0.79M | 1.50M | 2.00M | 4.46M | - |
| Depreciation | 0.16M | 0.10M | 0.11M | 0.07M | 0.07M |
| Change to inventory | -0.08M | 0.03M | 0.01M | -0.24M | -0.24M |
| Change to account receivables | -0.40M | -0.08M | -0.32M | -0.09M | -0.09M |
| Change to netincome | - | - | - | -0.14M | 0.01M |
| Capital expenditures | 0.27M | 0.15M | 0.01M | 0.06M | 0.06M |
| Change in working capital | 1.24M | -0.04M | -0.30M | -0.47M | 0.01M |
| Stock based compensation | 0.09M | 0.06M | 0.02M | 0.01M | - |
| Other non cash items | 0.05M | -0.13M | -0.00M | -0.15M | - |
| Free cash flow | -1.14M | -2.39M | -3.18M | -3.77M | -0.01M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AURX Nuo Therapeutics Inc |
-0.02 1.54% |
1.28 | - | - | 20.40 | 41.78 | 21.87 | -67.38 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. It serves hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.
| Name | Title | Year Born |
|---|---|---|
| Mr. David E. Jorden CPA | CEO, CFO, Sec. & Exec. Director | 1962 |
| Dr. Peter Anton Clausen Ph.D. | COO & Chief Scientific Officer | 1966 |
| Ms. Jennifer Grayson | Head of Comprehensive Clinical Trial Data Audit | NA |
| Mr. Shaun M. Martin | Chief Restructuring Officer | NA |
| Dr. David F. Counts | Consultant | NA |
| Mr. Joseph Del Guercio | Informal Board Advisor | 1972 |
| Mr. David E. Jorden CPA | CEO, CFO, Secretary & Executive Director | 1962 |
| Mr. Joseph A. Del Guercio | Informal Board Advisor | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...